BAX three-lens brief
Evidence-based stock research on BAX. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $22.12 — 22% above current (13 analysts). · Trading at 14% of its 52-week range — deep in the lower band.
- Trading at 14% of its 52-week range — deep in the lower band.
- Analyst mean target $22.12 — 22% above current (13 analysts).
- Debt-to-equity of 160.3 — balance-sheet-heavy.
BAX closed at $18.16 (-1.36%) as of 2026-04-25. Market cap: $9.38B. Positives: analyst mean target $22.12 — 22% above current (13 analysts).. Concerns: trading at 14% of its 52-week range — deep in the lower band.; debt-to-equity of 160.3 — balance-sheet-heavy.. Last quarter: Revenue $2.97B, net income $0.00, free cash flow $2.43B.
Why three lenses on BAX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BAXacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BAX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BAX brief"></iframe>